Sun Pharma successfully secured ₹7,816 crore in its latest fundraising round, yet it fell short of its ambitious ₹10,000-crore target. The company opted for five- and seven-year bonds, pricing them at 8.05% and 8.20% respectively. A significant ₹2,100 crore was raised through anchor investments to bolster this effort, although rising market yields have made investors cautious about committing funds.
Gold heads for sharpest weekly decline in four months on Fed rate outlook
Gold prices took a hit on Friday amid strong indicators of US economic growth and climbing oil prices. Spot gold prices sank to their lowest